{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T05:23:33Z","timestamp":1787289813014,"version":"build-2736575974"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy with poor prognosis. Surgery is the only curative option for ACC, but recurrence remains high. Effective systemic therapies are still lacking in ACC. Diagnosis currently relies on integrated hormonal, imaging, and histopathological assessments. However, distinguishing ACC from benign adrenocortical adenoma (ACA) remains challenging. To address this, we performed untargeted plasma metabolomics on patients with ACC and ACA, as well as on healthy controls, to identify differential metabolites and elucidate the enriched Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. Notably, glycocholic acid emerged as a significantly upregulated metabolite in ACC with superior diagnostic accuracy. Furthermore, a metabolic model incorporating six plasma metabolites, including glycocholic acid, distinguished ACC from ACA and healthy controls with an area under the curve (AUC) of 0.9266. These findings demonstrate that plasma metabolomics might serve as a promising tool for the detection of ACC.<\/jats:p>","DOI":"10.3389\/fphar.2026.1817514","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T04:23:39Z","timestamp":1787286219000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Plasma untargeted metabolomics reveals promising diagnostic metabolites for adrenocortical carcinoma"],"prefix":"10.3389","volume":"17","author":[{"given":"Yihui","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]},{"name":"State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuping","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]},{"name":"State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqiang","family":"Wu","sequence":"additional","affiliation":[{"name":"Center for Biomarker Discovery and Validation, National Infrastructure for Translational Medicine, Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]},{"name":"State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junmei","family":"Shang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]},{"name":"State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]},{"name":"State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]},{"name":"State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]},{"name":"State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3775","DOI":"10.1210\/jc.2011-1565","article-title":"Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors","volume":"96","author":"Arlt","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B2","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/s2213-8587(20)30218-7","article-title":"Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study","volume":"8","author":"Bancos","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/mou.0000000000001045","article-title":"Treatment of adrenocortical carcinoma: oncological and endocrine outcomes","volume":"33","author":"Br\u00f6nimann","year":"2023","journal-title":"Curr. Opin. Urol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e307","DOI":"10.1210\/clinem\/dgz141","article-title":"Urine steroid metabolomics as a novel tool for detection of recurrent adrenocortical carcinoma","volume":"105","author":"Chortis","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B5","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1093\/oncolo\/oyae029","article-title":"Adrenocortical carcinomas: molecular pathogenesis, treatment options, and emerging immunotherapy and targeted therapy approaches","volume":"29","author":"Chukkalore","year":"2024","journal-title":"Oncologist"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1111\/bcp.14721","article-title":"Pharmacological profile and effects of mitotane in adrenocortical carcinoma","volume":"87","author":"Corso","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1080\/14656566.2022.2106128","article-title":"Advances in adrenocortical carcinoma pharmacotherapy: what is the current state of the art?","volume":"23","author":"Cremaschi","year":"2022","journal-title":"Expert Opin. Pharmacother."},{"key":"B8","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/s41574-019-0221-7","article-title":"Adrenocortical carcinoma - towards genomics guided clinical care","volume":"15","author":"Crona","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"4925","DOI":"10.1210\/jc.2010-0803","article-title":"Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers","volume":"95","author":"Fassnacht","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B10","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur. J. Endocrinol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/S2213-8587(24)00378-4","article-title":"Adrenocortical carcinoma: a practical guide for clinicians","volume":"13","author":"Fassnacht","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"104839","DOI":"10.1016\/j.critrevonc.2025.104839","article-title":"The management of adrenocortical carcinoma in the era of precision medicine","volume":"214","author":"Flauto","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/s41568-023-00623-0","article-title":"Advances in translational research of the rare cancer type adrenocortical carcinoma","volume":"23","author":"Ghosh","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"961650","DOI":"10.3389\/fendo.2022.961650","article-title":"Pediatric adrenocortical carcinoma","volume":"13","author":"Ilanchezhian","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1530\/ERC-13-0232","article-title":"Metabolomic profile of the adrenal gland: from physiology to pathological conditions","volume":"20","author":"Imperiale","year":"2013","journal-title":"Endocr. Relat. Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1002\/bmc.3737","article-title":"Macromolecular crowding agents-assisted imprinted polymers for analysis of Glycocholic acid in human plasma and urine","volume":"30","author":"Li","year":"2016","journal-title":"Biomed. Chromatogr."},{"key":"B17","doi-asserted-by":"publisher","first-page":"100759","DOI":"10.1016\/j.ctarc.2023.100759","article-title":"Adrenocortical carcinoma: diagnosis, prognostic classification and treatment of localized and advanced disease","volume":"37","author":"Lib\u00e9","year":"2023","journal-title":"Cancer Treat. Res. Commun."},{"key":"B18","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/ijc.31323","article-title":"Investigation of the urinary metabolic variations and the application in bladder cancer biomarker discovery","volume":"143","author":"Liu","year":"2018","journal-title":"Int. J. Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s12022-022-09710-8","article-title":"Overview of the 2022 WHO classification of adrenal cortical tumors","volume":"33","author":"Mete","year":"2022","journal-title":"Endocr. Pathol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ando.2019.09.001","article-title":"Adrenocortical carcinoma: impact of surgical treatment","volume":"80","author":"Miralli\u00e9","year":"2019","journal-title":"Ann. Endocrinol. (Paris)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3390\/biomedicines9020174","article-title":"The role of biomarkers in adrenocortical carcinoma: a review of current evidence and future perspectives","volume":"9","author":"Mizdrak","year":"2021","journal-title":"Biomedicines"},{"key":"B22","doi-asserted-by":"publisher","first-page":"5292","DOI":"10.3390\/molecules27165292","article-title":"The bile acid membrane receptor TGR5 in cancer: friend or foe?","volume":"27","author":"Qi","year":"2022","journal-title":"Molecules"},{"key":"B23","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.3390\/ijms24043585","article-title":"Steroidogenic factor 1, a goldilocks transcription factor from adrenocortical organogenesis to malignancy","volume":"24","author":"Relav","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s11864-024-01249-6","article-title":"Systemic management of advanced adrenocortical carcinoma","volume":"25","author":"Russell","year":"2024","journal-title":"Curr. Treat. Options Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.2174\/0113892010298852240528123911","article-title":"Artificial intelligence in cancer diagnosis: a game-changer in healthcare","volume":"26","author":"Sahoo","year":"2025","journal-title":"Curr. Pharm. Biotechnol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.ucl.2025.01.009","article-title":"Update on adrenocortical carcinoma","volume":"52","author":"Sarrafan-Chaharsoughi","year":"2025","journal-title":"Urol. Clin. North Am."},{"key":"B27","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1530\/EJE-18-0782","article-title":"Plasma steroid metabolome profiling for the diagnosis of adrenocortical carcinoma","volume":"180","author":"Schweitzer","year":"2019","journal-title":"Eur. J. Endocrinol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"11088","DOI":"10.1038\/s41598-018-29445-z","article-title":"Discovery of glycocholic acid and taurochenodeoxycholic acid as phenotypic biomarkers in cholangiocarcinoma","volume":"8","author":"Song","year":"2018","journal-title":"Sci. Rep."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1097\/PAS.0b013e31825a6308","article-title":"Adrenocortical tumors: improving the practice of the Weiss system through virtual microscopy: a National Program of the French Network INCa-COMETE","volume":"36","author":"Tissier","year":"2012","journal-title":"Am. J. Surg. Pathol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00428-025-04278-0","article-title":"Diagnosis and grading of adrenal cortical carcinoma","volume":"488","author":"Vocino","year":"2026","journal-title":"Virchows Arch."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1515\/cclm-2024-1337","article-title":"An untargeted metabolomics approach to evaluate enzymatically deconjugated steroids and intact steroid conjugates in urine as diagnostic biomarkers for adrenal tumors","volume":"63","author":"Vogg","year":"2025","journal-title":"Clin. Chem. Lab. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1210\/clinem\/dgad559","article-title":"Cerebrospinal fluid metabolomic pattern of different pituitary stalk lesions","volume":"109","author":"Wang","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B33","doi-asserted-by":"publisher","first-page":"pkaf086","DOI":"10.1093\/jncics\/pkaf086","article-title":"Pre-diagnostic circulating bile acid concentrations and liver cancer risk: a nested case-control analysis of 12 cohorts","volume":"9","author":"Watling","year":"2025","journal-title":"JNCI Cancer Spectr."},{"key":"B34","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2174\/2213235X04666160613122429","article-title":"PCA as a practical indicator of OPLS-DA model reliability","volume":"4","author":"Worley","year":"2016","journal-title":"Curr. Metabolomics"},{"key":"B35","doi-asserted-by":"publisher","first-page":"110508","DOI":"10.1016\/j.cellsig.2022.110508","article-title":"Glycocholic acid aggravates liver fibrosis by promoting the up-regulation of connective tissue growth factor in hepatocytes","volume":"101","author":"Yuan","year":"2023","journal-title":"Cell Signal"},{"key":"B36","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.cca.2012.12.024","article-title":"Urinary metabolic profiling identifies a key role for glycocholic acid in human liver cancer by ultra-performance liquid-chromatography coupled with high-definition mass spectrometry","volume":"418","author":"Zhang","year":"2013","journal-title":"Clin. Chim. Acta"},{"key":"B37","doi-asserted-by":"publisher","first-page":"4893","DOI":"10.1038\/s41467-026-71403-1","article-title":"Inhibition of circulating glycocholic acid-regulated signaling potentiates immune checkpoint therapy in colorectal cancer","volume":"17","author":"Zhao","year":"2026","journal-title":"Nat. Commun."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1817514\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T04:23:40Z","timestamp":1787286220000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1817514\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":37,"alternative-id":["10.3389\/fphar.2026.1817514"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1817514","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"article-number":"1817514"}}